Paper33352201
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Yhim HY and 10 others. Ann Oncol, 2021. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial. Papers, record 33352201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33352201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lymphoma, T-Cell, Peripheral | Major topic |
| Deoxycytidine | |
| Humans | |
| Neoplasm Recurrence, Local | |
| Pyrimidines | |
| Quinazolines | |
| Treatment Outcome | |
| Gemcitabine |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41975188 | Annexin A3 potentiates lenvatinib resistance in hepatocellular carcinoma through multiple approaches amplified by a positive feedback loop. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41975188 | PubMed |
| 41535417 | Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41535417 | PubMed |
| 41394820 | Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/41394820 | PubMed |
| 41105775 | Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup. | Sci Adv | 2025 | https://conductscience.org/library/papers/41105775 | PubMed |
| 40098700 | Advancing the understanding and management of angioimmunoblastic T-cell lymphoma: insights into its pathogenesis, clinical features, and emerging therapeutic strategies. | Front Oncol | 2025 | https://conductscience.org/library/papers/40098700 | PubMed |
| 39175124 | Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma. | Chin Med J (Engl) | 2024 | https://conductscience.org/library/papers/39175124 | PubMed |
| 38824603 | Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/38824603 | PubMed |
| 38486980 | Small-molecule agents for cancer immunotherapy. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38486980 | PubMed |
| 37596643 | PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37596643 | PubMed |
| 37188182 | Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL). | Front Oncol | 2023 | https://conductscience.org/library/papers/37188182 | PubMed |
| 36900160 | Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36900160 | PubMed |
| 36773078 | Development and safety of PI3K inhibitors in cancer. | Arch Toxicol | 2023 | https://conductscience.org/library/papers/36773078 | PubMed |
| 36765544 | Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765544 | PubMed |
| 35626087 | Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35626087 | PubMed |
| 35565460 | Peripheral T-Cell Lymphomas: Therapeutic Approaches. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35565460 | PubMed |
| 34072040 | Targeted Approaches to T-Cell Lymphoma. | J Pers Med | 2021 | https://conductscience.org/library/papers/34072040 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TSC2 | 7249 | PubTator's text mining | https://conductscience.org/library/genes/7249 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33352201
GET https://conductscience.org/api/papers/v1/33352201/authors